Deubiquitinases as pivotal regulators of T cell functions
- PMID: 30054854
- PMCID: PMC6705128
- DOI: 10.1007/s11684-018-0651-y
Deubiquitinases as pivotal regulators of T cell functions
Abstract
T cells efficiently respond to foreign antigens to mediate immune responses against infections but are tolerant to self-tissues. Defect in T cell activation is associated with severe immune deficiencies, whereas aberrant T cell activation contributes to the pathogenesis of diverse autoimmune and inflammatory diseases. An emerging mechanism that regulates T cell activation and tolerance is ubiquitination, a reversible process of protein modification that is counter-regulated by ubiquitinating enzymes and deubiquitinases (DUBs). DUBs are isopeptidases that cleave polyubiquitin chains and remove ubiquitin from target proteins, thereby controlling the magnitude and duration of ubiquitin signaling. It is now well recognized that DUBs are crucial regulators of T cell responses and serve as potential therapeutic targets for manipulating immune responses in the treatment of immunological disorders and cancer. This review will discuss the recent progresses regarding the functions of DUBs in T cells.
Keywords: T cell activation; T cell differentiation; T cell tolerance; deubiquitinase; ubiquitination.
Figures
Similar articles
-
Deubiquitinases: From mechanisms to their inhibition by small molecules.Mol Cell. 2022 Jan 6;82(1):15-29. doi: 10.1016/j.molcel.2021.10.027. Epub 2021 Nov 22. Mol Cell. 2022. PMID: 34813758 Review.
-
The role of deubiquitinases in breast cancer.Cancer Metastasis Rev. 2016 Dec;35(4):589-600. doi: 10.1007/s10555-016-9640-2. Cancer Metastasis Rev. 2016. PMID: 27844253 Free PMC article. Review.
-
Regulation of T cell differentiation and function by ubiquitin-specific proteases.Cell Immunol. 2019 Jun;340:103922. doi: 10.1016/j.cellimm.2019.103922. Epub 2019 May 3. Cell Immunol. 2019. PMID: 31078284 Review.
-
Regulation of T helper cell differentiation by E3 ubiquitin ligases and deubiquitinating enzymes.Int Immunopharmacol. 2017 Jan;42:150-156. doi: 10.1016/j.intimp.2016.11.013. Epub 2016 Nov 30. Int Immunopharmacol. 2017. PMID: 27914308 Review.
-
DUBs, Hypoxia, and Cancer.Trends Cancer. 2019 Oct;5(10):632-653. doi: 10.1016/j.trecan.2019.08.005. Epub 2019 Oct 11. Trends Cancer. 2019. PMID: 31706510 Review.
Cited by
-
USP1-regulated reciprocal differentiation of Th17 cells and Treg cells by deubiquitinating and stabilizing TAZ.Cell Mol Immunol. 2023 Mar;20(3):252-263. doi: 10.1038/s41423-022-00969-9. Epub 2023 Jan 5. Cell Mol Immunol. 2023. PMID: 36600049 Free PMC article.
-
Targeting ubiquitin signaling for cancer immunotherapy.Signal Transduct Target Ther. 2021 Jan 13;6(1):16. doi: 10.1038/s41392-020-00421-2. Signal Transduct Target Ther. 2021. PMID: 33436547 Free PMC article. Review.
-
E3 Ubiquitin Ligases as Immunotherapeutic Target in Atherosclerotic Cardiovascular Disease.Front Cardiovasc Med. 2020 Jun 5;7:106. doi: 10.3389/fcvm.2020.00106. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 32582770 Free PMC article. Review.
-
Regulation of Deubiquitinating Enzymes by Post-Translational Modifications.Int J Mol Sci. 2020 Jun 4;21(11):4028. doi: 10.3390/ijms21114028. Int J Mol Sci. 2020. PMID: 32512887 Free PMC article. Review.
-
Foxp3 Post-translational Modifications and Treg Suppressive Activity.Front Immunol. 2019 Oct 18;10:2486. doi: 10.3389/fimmu.2019.02486. eCollection 2019. Front Immunol. 2019. PMID: 31681337 Free PMC article. Review.
References
-
- Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005; 435(7042): 590–597 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources